NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

NCT00163189

CompletedPhase 3

Sponsor: Pfizer

Conditions: Growth Hormone Deficiency

Interventions: Somatropin

Countries: France

To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Glucocorticosteroid treatment for 12 months at least
* Bone age \< 15 years for a boy and \< 13 years for a girl
* Child measured height \< - 2 SD, Child currently treated by GH

Exclusion Criteria:

* Known diabetes (type 1 or type 2)
* A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures

Locations (19)

Amiens, France
Annemasse, France
Besançon, France
Bron, France
Bron, France
Clermont-Ferrand, France
Grenoble, France
Marseille, France
Montpellier, France
Nantes, France
Nice, France
Paris, France
Paris, France
Paris, France
Roscoff, France
Rouen, France
Saint-Germain-en-Laye, France
Toulouse, France
Tours, France